HedgeChatter

  • Home /
  • Tag Archives

EPZM

Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone

[at noodls] – CAMBRIDGE, Mass., Feb. 27, 2014 /PRNewswire/ — Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined … moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 27, 2014 Bystocknews , Comments Off on Epizyme Achieves Lead Candidate Selection Milestone in GSK Collaboration, Earning $2 Million Milestone read more

8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 24, 2014 Bystocknews , Comments Off on 8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo read more

8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo

moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on 8:14 am Epizyme announces publication of preclinical data demonstrating clinical candidate EPZ-6438 as potent and selective inhibitor of EZH2 in genetically defined non-Hodgkin lymphoma; preclinical study results published in the Journal Mo read more

Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma

[PR Newswire] – CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ — Epizyme, Inc., (EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 21, 2014 Bystocknews , Comments Off on Epizyme Announces Publication of Preclinical Data Demonstrating Clinical Candidate EPZ-6438 as Potent and Selective Inhibitor of EZH2 in Genetically Defined Non-Hodgkin Lymphoma read more

Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014

[PR Newswire] – CAMBRIDGE, Mass., Feb. 19, 2014 /PRNewswire/ — Epizyme, Inc., (EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it will hos moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 19, 2014 Bystocknews , Comments Off on Epizyme, Inc. to Report Fourth Quarter and Year-End 2013 Financial Results on February 27, 2014 read more

Epizyme Announces Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock

[PR Newswire] – CAMBRIDGE, Mass., Feb. 11, 2014 /PRNewswire/ — Epizyme, Inc. (EPZM), a clinical stage biopharmaceutical company that is discovering, developing and planning to commercialize innovative personalized therapeutics for patients with genetica moreView todays social media effects on EPZMView the latest stocks trending across Twitter. Click to view dashboardSee who Epizyme is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on Epizyme Announces Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock read more